ten23 health AG
ten23 health is a pharmaceutical CDMO (contract development and manufacturing organization). We offer solutions for the pharmaceutical industry and biotech start-ups for the development, manufacture, and testing of tomorrow’s medicines. We support our clients in developing differentiated, stable, usable, and safe injectable treatments for patients.
Year of listing
Industry
2022
Pharmaceuticals & Supplies
Basel
Region
Size
50-249
Pledges
Direct contribution to SDGs
Type of Pledge
Goal 1
By 2025, we remove twice as much plastic from the environment than we send to final disposal*.
* On an annual basis, by combining measures of reduction, substitution, recycling, and plastic-offsetting (removing existing plastic from the oceans with partner organizations). Final disposal means incineration or landfill.
Core business
Goal 2
By 2025, we reduce our greenhouse gas emissions by 50 % on Scopes 1 & 2, committing to being part of the Science Based Targets initiative (SBTi)*.
* On a 2021 basis, pro rata to the months of activity in the year.
Internal operations
Goal 3
By 2023, we achieve equal treatment of all employees in the workspace, ensuring no gender pay gap*.
* Carried out by third-party assessment.
Internal operations
Goal 4
By 2023, we promote diversity in the workspace by targeting minimum 50% non-cis-male employees and obtaining the Swiss LGBTI label certification*.
* Carried out by third-party assessment.
Internal operations
Scope of Pledges:
ten23 health operates in Switzerland through several subsidiaries. The company is represented by ten23 health AG in Basel and Swissfillon AG in Visp. The pledges taken within the STI framework relate to the fairstainability policy applying to all ten23 health operations carried out in Switzerland. The company is therefore accountable for their implementation within the limits of its scope of activity.
Note: By 2023 systematically indicates the end of the year, meaning: By the end of 2023 (unless otherwise defined, such as fiscal year)
Other Commitments
